<DOC>
	<DOCNO>NCT01161914</DOCNO>
	<brief_summary>The purpose study compare evaluate efficacy safety ISU302 , investigational product , Cerezyme® , comparator , Type 1 Gaucher Disease patient</brief_summary>
	<brief_title>The Safety Efficacy Study ISU302 Patient With Type I Gaucher Disease</brief_title>
	<detailed_description />
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>The subject diagnosis Type I Gaucher Disease Subjects 2 year old 75 year old Subjects document glucocerebrosidase deficiency Subjects splenomegaly ( indicated CT volumetric analysis 5 time standard size ( 0.2 % total body weight kilogram ) ) A hemoglobin concentration level : Male &gt; 12 year age &lt; 12.0 g/dL Female &gt; 12 year age &lt; 11.0 g/dL Child &gt; 2 year age &lt; 12 year age &lt; 10.5 g/dL Platelet count &lt; 120,000 / ㎣ Treatmentnaive enzyme replacement therapy ( ERT ) treatment experienced subject receive ERT 12 month screen antibody test result negative Treatment naive substrate reduction therapy ( SRT ) treatment experienced subject receive SRT 12 month screen Subjects spouse provide consent use one follow contraception method , woman menopause . ( In case , menopause define period 12 month last menstruation ) Condoms , sponge , foam , jelly , diaphragm , intrauterine device ( Spouse patient vasectomy tubal ligation/ hysterectomy ) Total abstinence sexual intercourse : Female patient use oral contraceptive must use contraception method ( barrier method ) also trial period completion trial well 90 day conclusion trial . The subject legal representative sign informed consent . Treatment investigational product 90 day study entry Partial total splenectomy Subjects serious concurrent disease like infection abuse addictive drug substance . Pregnant and/or breastfeed woman Presence Hepatitis B surface antigen Hepatitis C patient show positive reaction human immunodeficiency virus ( HIV ) type1 Subjects history allergic reaction Imiglucerase Subjects history severe pulmonary hypertension cause Gaucher Disease Any subject investigator sub investigator considers inad equate trial</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Type I Gaucher</keyword>
</DOC>